A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed, symptomatic multiple myeloma patients who are eligible for high dose therapy and autologous stem cell transplantation.

Trial Profile

A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed, symptomatic multiple myeloma patients who are eligible for high dose therapy and autologous stem cell transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary) ; Low molecular weight heparin; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RAD
  • Most Recent Events

    • 25 Jun 2017 Final results of the Greek Myeloma Study Group, presented at the 22nd Congress of the European Haematology Association
    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results (cut off data February 2016, n=45) assessing efficacy of RAD as induction therapy for NDMM patients, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top